MX362675B - Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. - Google Patents
Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.Info
- Publication number
- MX362675B MX362675B MX2015003772A MX2015003772A MX362675B MX 362675 B MX362675 B MX 362675B MX 2015003772 A MX2015003772 A MX 2015003772A MX 2015003772 A MX2015003772 A MX 2015003772A MX 362675 B MX362675 B MX 362675B
- Authority
- MX
- Mexico
- Prior art keywords
- gastrine
- liberating
- receptors
- antigonists
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705513P | 2012-09-25 | 2012-09-25 | |
| PCT/US2013/061712 WO2014052471A1 (en) | 2012-09-25 | 2013-09-25 | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003772A MX2015003772A (es) | 2015-11-09 |
| MX362675B true MX362675B (es) | 2019-01-30 |
Family
ID=49887190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003772A MX362675B (es) | 2012-09-25 | 2013-09-25 | Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US9839703B2 (enExample) |
| EP (2) | EP3536347A1 (enExample) |
| JP (4) | JP6562838B2 (enExample) |
| KR (2) | KR102314293B1 (enExample) |
| AU (4) | AU2013323596C1 (enExample) |
| BR (1) | BR112015006453B1 (enExample) |
| CA (2) | CA3114832A1 (enExample) |
| DK (1) | DK2900279T3 (enExample) |
| ES (1) | ES2745635T3 (enExample) |
| HR (1) | HRP20191620T1 (enExample) |
| HU (1) | HUE045724T2 (enExample) |
| IL (4) | IL276300B2 (enExample) |
| LT (1) | LT2900279T (enExample) |
| MX (1) | MX362675B (enExample) |
| PL (1) | PL2900279T3 (enExample) |
| PT (1) | PT2900279T (enExample) |
| RU (1) | RU2693465C9 (enExample) |
| SI (1) | SI2900279T1 (enExample) |
| WO (1) | WO2014052471A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841238C (en) * | 2011-07-08 | 2019-10-01 | Biosynthema Inc. | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| ES2745635T3 (es) * | 2012-09-25 | 2020-03-03 | Advanced Accelerator Applications Usa Inc | Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR |
| EP3015462A1 (en) * | 2014-10-29 | 2016-05-04 | OctreoPharm Schiences GmbH | Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals |
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| WO2018096082A1 (en) | 2016-11-28 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
| SI3568205T1 (sl) | 2017-01-12 | 2023-12-29 | Radiomedix Inc. | Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope |
| JP7480132B2 (ja) * | 2018-10-12 | 2024-05-09 | アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ．アー． | 放射性標識されたｇｐｒｐアンタゴニスト及び界面活性剤を含む医薬組成物 |
| JP7502801B2 (ja) * | 2018-11-13 | 2024-06-19 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物 |
| MY208484A (en) | 2018-11-23 | 2025-05-13 | Bayer Pharma AG | Formulation of contrast media and process of preparation thereof |
| CN114728088A (zh) * | 2019-09-16 | 2022-07-08 | 诺华股份有限公司 | 稳定的浓缩的放射性药物组合物 |
| TWI878344B (zh) * | 2019-09-17 | 2025-04-01 | 瑞士商諾華公司 | 放射性標記grpr拮抗劑之方法及其套組 |
| CA3155462A1 (en) * | 2019-09-24 | 2021-04-01 | Novartis Ag | Radiolabelled grpr-antagonist for use as theragnostic |
| EP4076541A1 (en) * | 2019-12-19 | 2022-10-26 | Technische Universität München | Modified grpr antagonist peptides for imaging and therapy of cancer |
| CA3246188A1 (en) | 2022-03-25 | 2023-09-28 | The University Of British Columbia | Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019647A (en) * | 1988-05-24 | 1991-05-28 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US4943561A (en) | 1988-11-28 | 1990-07-24 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US5028692A (en) | 1989-04-25 | 1991-07-02 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| KR920701242A (ko) * | 1989-11-06 | 1992-08-11 | 원본미기재 | 환원된 비가역성 봄베신 길항제 |
| AU668909B2 (en) | 1992-02-07 | 1996-05-23 | Merrell Dow Pharmaceuticals Inc. | Phenylalanine analogs of bombesin |
| US5620955A (en) * | 1993-06-18 | 1997-04-15 | Peptide Technologies Corporation | Bombesin receptor antagonists and uses thereof |
| WO1999025729A1 (fr) | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Composes possedant une activite antitumorale |
| KR101106533B1 (ko) | 2003-07-24 | 2012-01-20 | 브라코 이미징 에스.피.에이. | 안정한 방사성의약 조성물 및 제조 방법 |
| EP2100900A1 (en) * | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| WO2012069410A1 (en) | 2010-11-22 | 2012-05-31 | Bayer Pharma Aktiengesellschaft | 177lutetium-labeled bombesin analogs for radiotherapy |
| CA2841238C (en) * | 2011-07-08 | 2019-10-01 | Biosynthema Inc. | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| ES2745635T3 (es) * | 2012-09-25 | 2020-03-03 | Advanced Accelerator Applications Usa Inc | Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR |
-
2013
- 2013-09-25 ES ES13815181T patent/ES2745635T3/es active Active
- 2013-09-25 WO PCT/US2013/061712 patent/WO2014052471A1/en not_active Ceased
- 2013-09-25 CA CA3114832A patent/CA3114832A1/en active Pending
- 2013-09-25 PL PL13815181T patent/PL2900279T3/pl unknown
- 2013-09-25 CA CA2886068A patent/CA2886068C/en active Active
- 2013-09-25 KR KR1020207034970A patent/KR102314293B1/ko active Active
- 2013-09-25 HR HRP20191620 patent/HRP20191620T1/hr unknown
- 2013-09-25 MX MX2015003772A patent/MX362675B/es active IP Right Grant
- 2013-09-25 EP EP19170067.3A patent/EP3536347A1/en active Pending
- 2013-09-25 HU HUE13815181A patent/HUE045724T2/hu unknown
- 2013-09-25 AU AU2013323596A patent/AU2013323596C1/en active Active
- 2013-09-25 IL IL276300A patent/IL276300B2/en unknown
- 2013-09-25 KR KR1020157007572A patent/KR102190005B1/ko active Active
- 2013-09-25 LT LT13815181T patent/LT2900279T/lt unknown
- 2013-09-25 SI SI201331585T patent/SI2900279T1/sl unknown
- 2013-09-25 RU RU2015115529A patent/RU2693465C9/ru active
- 2013-09-25 US US14/431,096 patent/US9839703B2/en active Active
- 2013-09-25 JP JP2015534625A patent/JP6562838B2/ja active Active
- 2013-09-25 PT PT138151816T patent/PT2900279T/pt unknown
- 2013-09-25 BR BR112015006453-1A patent/BR112015006453B1/pt active IP Right Grant
- 2013-09-25 EP EP13815181.6A patent/EP2900279B1/en active Active
- 2013-09-25 DK DK13815181.6T patent/DK2900279T3/da active
-
2015
- 2015-03-19 IL IL237844A patent/IL237844B/en active IP Right Review Request
-
2017
- 2017-11-20 US US15/817,776 patent/US20180133349A1/en not_active Abandoned
- 2017-12-28 IL IL256649A patent/IL256649B/en active IP Right Grant
-
2018
- 2018-06-21 AU AU2018204513A patent/AU2018204513C1/en active Active
-
2019
- 2019-06-04 JP JP2019104379A patent/JP6997135B2/ja active Active
- 2019-08-16 AU AU2019216714A patent/AU2019216714B2/en active Active
- 2019-09-24 US US16/580,990 patent/US11083805B2/en active Active
-
2021
- 2021-03-26 AU AU2021201914A patent/AU2021201914B2/en active Active
- 2021-07-23 US US17/383,577 patent/US12064491B2/en active Active
- 2021-07-23 US US17/383,550 patent/US12064489B2/en active Active
- 2021-07-23 US US17/383,567 patent/US12064490B2/en active Active
- 2021-09-22 JP JP2021154188A patent/JP7358430B2/ja active Active
-
2023
- 2023-07-13 JP JP2023115231A patent/JP7534498B2/ja active Active
-
2024
- 2024-05-02 IL IL312551A patent/IL312551B2/en unknown
- 2024-07-15 US US18/773,055 patent/US20240366812A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX362675B (es) | Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. | |
| WO2009129311A3 (en) | Somatostatin receptor 2 antagonists | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| CU20190056A7 (es) | Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas | |
| BR112012018132A2 (pt) | "marcadores de células - tronco tumorais e uso dos mesmos". | |
| NZ700823A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
| CL2016000883A1 (es) | Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma. | |
| MA40074A (fr) | Composés liant ras multivalents | |
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| EP3906945A3 (en) | Nucleic acids encoding human antibodies to sialyl-lewis a | |
| NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| EA201301334A1 (ru) | Меченные радиоактивными изотопами ингибиторы глутаминилциклазы | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| NZ594480A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| CR11396A (es) | Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas | |
| AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| MY185593A (en) | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | |
| MX2015012528A (es) | Inhibidores macrociclicos de cinasa inducibles por sal. | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| BR112013004850A2 (pt) | tratamento de infarto do miocárdio usando antagonistas tgf-beta | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| MA40592A (fr) | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 | |
| MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |